Brachytherapy News and Research

RSS

Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.

External beam partial breast irradiation most cost-effective treatment for women with early-stage breast cancer

External beam partial breast irradiation (EB-PBI) is the most cost-effective method for treating postmenopausal women with early-stage breast cancer based on utilities, recurrence risks and costs when compared to whole breast radiotherapy (WBRT) and brachytherapy partial breast irradiation (brachy-PBI), according to a study in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

2 Jun 2009

Low oxygen levels in prostate tumors can predict recurrence

Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer.

17 May 2009

Radiation device in the breast reduces complications for early stage breast cancer patients

A new study shows that the SAVI™ applicator, a small, expandable device inserted inside the breast to deliver partial breast irradiation, carries a low infection risk, a potential complication of such devices.

23 Apr 2009

Exposure to Agent Orange increases risk of aggressive recurrence of prostate cancer

Veterans exposed to Agent Orange are at increased risk of aggressive recurrence of prostate cancer, researchers report.

20 Apr 2009

High dosage brachytherapy obtains excellent results in head and neck tumors

High-dosage perioperative brachytherapy (applied within the surgical process) obtains excellent results in the treatment of head and neck tumours, at the same time as reducing the period of radiation.

29 Mar 2009

Promising results for 5-day stereotactic body radiation therapy in early stage prostate cancer

Preliminary results show that a shortened course of radiation therapy for prostate cancer called stereotactic body radiation therapy (SBRT) provides good PSA response for early-stage prostate cancer and has the same side effects as other treatments, according to a March 15 study in the International Journal of Radiation Oncology*Biology*Physics , the official journal of the American Society for Radiation Oncology (ASTRO).

16 Mar 2009

Radioactive bone cement may be a new treatment option for breast cancer

For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission.

22 Feb 2009

First-degree family history of prostate cancer does not affect some treatment outcomes

In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the International Journal of Radiation Oncology*Biology*Physics , the official journal of the American Society for Radiation Oncology.

5 Jan 2009

FDA grants compassionate case for use of novel wet age-related macular degeneration treatment

NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols.

10 Dec 2008

UK's first prostate cancer patient treated using RapidArc radiotherapy

65-year-old grandfather of six, Graham McCormack has become the first cancer patient in the UK to be treated using RapidArc radiotherapy technology from Varian Medical Systems.

10 Dec 2008

Breast cancer treatment offers better outcome to women with implants

Women with early-stage breast cancer who have undergone breast augmentation may be treated successfully with a partial-breast radiation treatment called brachytherapy, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2008

One week radiation treatment for breast cancer as effective as standard 6 to 7 week course

A new type of radiation treatment rapidly speeds up treatment for some breast cancer sufferers.

24 Sep 2008

Brachytherapy may benefit obese prostate cancer patients

Brachytherapy, also called seed implants, may be a more beneficial treatment than surgery or external beam radiation therapy for overweight or obese prostate cancer patients, according to a study published in the August issue of the International Journal of Radiation Oncology-Biology-Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

19 Aug 2008

FDA approves expansion of NeoVista's phase 3 study for wet AMD

NeoVista, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company's request to expand the number of sites participating in its pivotal Phase 3 trial from 10 to 30 in the United States.

17 Apr 2008

Prostate size and other neglected factors influence prostate cancer treatment satisfaction

Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.

20 Mar 2008

New study confirms that PROGENSA PCA3 can improve accuracy of prostate cancer diagnosis

New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.

20 Mar 2008

Many prostate cancer patients receive wrong treatment

Prostate cancer patients often receive treatment that is contraindicated by pre-existing conditions, like urinary or bowel dysfunction, according to a new study.

26 Nov 2007

New device delivers radiation therapy to specific tumor sites

Physicians at the Rebecca and John Moores UCSD Cancer Center will present the initial outcomes of their use of a new device that delivers radiation therapy to a specific tumor site at the annual meeting of the Radiological Society of North America (RSNA), November 25-30, 2007, in Chicago, Illinois.

19 Nov 2007

Radiation seed implant decreases risk of death over watchful waiting/active surveillance for prostate cancer

Prostate cancer patients cut their risk of dying of the disease in half when they receive radiation seed implants (brachytherapy) to treat their cancer, compared to those who don't receive active treatment (watchful waiting/active surveillance), within six months from being diagnosed with localized prostate cancer, according to a study presented October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

1 Nov 2007

Brachytherapy effectively cures prostate cancer in young men

Radiation seed implants (brachytherapy) are just as effective at curing prostate cancer in younger men (aged 60 and younger) as they are in older men, according to a study presented at a scientific session on October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007